Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 3, Multicenter, Double-Blind, Randomized, Vehicle Controlled Clinical Study to Assess the Safety and Efficacy of IDP-122 in the Treatment of Plaque Psoriasis

Next Previous
Trial Profile

A Phase 3, Multicenter, Double-Blind, Randomized, Vehicle Controlled Clinical Study to Assess the Safety and Efficacy of IDP-122 in the Treatment of Plaque Psoriasis

Status: Completed
Phase of Trial: Phase III

Latest Information Update: 29 Jan 2020

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Ulobetasol (Primary)
  • Indications Plaque psoriasis
  • Focus Registrational; Therapeutic Use
  • Sponsors Bausch Health Companies; Valeant Pharmaceuticals International

Most Recent Events

  • 07 Nov 2018 According to a Bausch Health Companies Inc. media release, the U.S. FDA gave final approval for BRYHALI Lotion on Nov. 6, 2018, indicated for the topical treatment of plaque psoriasis in adult patients. BRYHALI Lotion had initially received a tentative approval from the FDA due to the pending expiration of exclusivity for a related product.
  • 07 Nov 2018 According to a Bausch Health Companies media release, Lawrence J. Green, M.D., (associate clinical professor of Dermatology at George Washington University School of Medicine in Washington, D.C) is the lead investigator of this trial.
  • 08 Oct 2018 Results presented in the Bausch Health Companies media release.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top